Abstract
Introduction: Fetal microchimerism could be involved in the regulation of breast cancer oncogenesis. CD34+ cells could be of a particular interest as up to 12% of the CD34+ population in maternal blood are of fetal origin. The aim of this research was to analyze the impact of umbilical cord blood (UCB) CD34+ on MCF-7 and MDA-MB-231 breast cancer cell lines, in order to uncover novel biological mechanisms and suggest novel treatment options for breast cancer. Methods: UCB CD34+ cells were obtained from healthy women at full-term delivery. Direct cultures were grown with MCF-7 and MDA-MB-231 cells. Proliferation, migration, invasion, and transcriptomic analysis of breast cancer cell lines were compared between cultures exposed and nonexposed to UCB CD34+ cells. Interactions between UCB CD34+ and breast cancer cells were analyzed under fluorescent microscopy. Functional analyses were generated with QIAGEN’s Ingenuity Pathway Analysis (IPA) and Gene Set Enrichment Analysis (GSEA). Results: Direct contact between UCB CD34+ and breast cancer cell lines induced a reduction in the proliferative capacities of MCF-7 and MDA-MB-231 and diminished the migration abilities of MDA-MB-231 cells. In 3D coculture, UCB CD34+ cells were attracted by tumor spheroids and incorporated into tumor cells. These cell-to-cell interactions were responsible for transcriptome modifications coherent with observed functional modifications. Among the cytokines secreted by UCB CD34+, IFN-γ was identified as a potential upstream regulator responsible for the molecular modifications observed in transcriptomic analysis of MCF-7 breast cancer cells exposed to UCB CD34+ cells, as was IL-17A in MDA-MB-231 cells. Conclusion: Direct cell-to-cell contact induced functional modifications in breast cancer cells. Interactions between UCB CD34+ and breast cancer cells could induce cell fusion and signal transmission via cytokines. Further analysis of direct cell-to-cell interactions should be performed at a molecular level to further understand the potential role of fetal CD34+ cells in breast cancer.
Journal Section:
Developmental Biology / Research Article
References
1.
UNICANCER
. Les chiffres du cancer en France
; 2021
. Available form: http://www.unicancer.fr/le-groupeunicancer/les-chiffres-cles/les-chiffres-du-cancer-en-france2.
Migliavacca Zucchetti
B
, Peccatori
FA
, Codacci-Pisanelli
G
. Pregnancy and lactation: risk or protective factors for breast cancer
. Adv Exp Med Biol
. 2020
;1252
:195
–7
. 3.
Froehlich
K
, Schmidt
A
, Heger
JI
, Al-Kawlani
B
, Aberl
CA
, Jeschke
U
, et al. Breast cancer, placenta and pregnancy
. Eur J Cancer
. 2019
;115
:68
–78
. 4.
Husby
A
, Wohlfahrt
J
, Øyen
N
, Melbye
M
. Pregnancy duration and breast cancer risk
. Nat Commun
. 2018
;9
(1
):4255
. 5.
Mathelin
C
, Youssef
C
, Brettes
JP
, Rio
MC
. [Paradoxical interactions between pregnancy and breast cancer]
. Gynecol Obstet Fertil
. 2007
;35
(5
):449
–56
. 6.
Lambe
M
, Hsieh
C
, Tsaih
S
, Ekbom
A
, Adami
HO
, Trichopoulos
D
. Maternal risk of breast cancer following multiple births: a nationwide study in Sweden
. Cancer Causes Control
. 1996
;7
(5
):533
–8
. 7.
Hsieh
C
, Wuu
J
, Trichopoulos
D
, Adami
HO
, Ekbom
A
. Gender of offspring and maternal breast cancer risk
. Int J Cancer
. 1999
;81
(3
):335
–8
. 8.
Gadi
VK
, Nelson
JL
. Fetal microchimerism in women with breast cancer
. Cancer Res
. 2007
;67
(19
):9035
–8
. 9.
Gadi
VK
, Malone
KE
, Guthrie
KA
, Porter
PL
, Nelson
JL
. Case-control study of fetal microchimerism and breast cancer
. PLoS One
. 2008
;3
(3
):e1706
. 10.
Gammill
HS
, Nelson
JL
. Naturally acquired microchimerism
. Int J Dev Biol
. 2010
;54
(2–3
):531
–43
. 11.
Khosrotehrani
K
, Bianchi
DW
. Multi-lineage potential of fetal cells in maternal tissue: a legacy in reverse
. J Cell Sci
. 2005
;118
(Pt 8
):1559
–63
. 12.
O’Donoghue
K
, Chan
J
, de la Fuente
J
, Kennea
N
, Sandison
A
, Anderson
JR
, et al. Microchimerism in female bone marrow and bone decades after fetal mesenchymal stem-cell trafficking in pregnancy
. Lancet
. 2004
;364
(9429
):179
–82
. 13.
Mikhail
MA
, M’Hamdi
H
, Welsh
J
, Levicar
N
, Marley
SB
, Nicholls
JP
, et al. High frequency of fetal cells within a primitive stem cell population in maternal blood
. Hum Reprod
. 2008
;23
(4
):928
–33
. 14.
Bianchi
DW
, Zickwolf
GK
, Weil
GJ
, Sylvester
S
, DeMaria
MA
. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum
. Proc Natl Acad Sci USA
. 1996
;93
(2
):705
–8
. 15.
Khosrotehrani
K
, Reyes
RR
, Johnson
KL
, Freeman
RB
, Salomon
RN
, Peter
I
, et al. Fetal cells participate over time in the response to specific types of murine maternal hepatic injury
. Hum Reprod
. 2007
;22
(3
):654
–61
. 16.
Nassar
D
, Khosrotehrani
K
, Aractingi
S
. Fetal microchimerism in skin wound healing
. Chimerism
. 2012
;3
(2
):45
–7
. 17.
Nassar
D
, Droitcourt
C
, Mathieu-d’Argent
E
, Kim
MJ
, Khosrotehrani
K
, Aractingi
S
. Fetal progenitor cells naturally transferred through pregnancy participate in inflammation and angiogenesis during wound healing
. FASEB J
. 2012
;26
(1
):149
–57
. 18.
Nguyen Huu
S
, Oster
M
, Uzan
S
, Chareyre
F
, Aractingi
S
, Khosrotehrani
K
. Maternal neoangiogenesis during pregnancy partly derives from fetal endothelial progenitor cells
. Proc Natl Acad Sci USA
. 2007
;104
(6
):1871
–6
. 19.
Nguyen Huu
S
, Khosrotehrani
K
, Oster
M
, Moguelet
P
, Espié
MJ
, Aractingi
S
. Early phase of maternal skin carcinogenesis recruits long-term engrafted fetal cells
. Int J Cancer
. 2008
;123
(11
):2512
–7
. 20.
Khosrotehrani
K
, Johnson
KL
, Cha
DH
, Salomon
RN
, Bianchi
DW
. Transfer of fetal cells with multilineage potential to maternal tissue
. JAMA
. 2004
;292
(1
):75
–80
. 21.
Dubernard
G
, Aractingi
S
, Oster
M
, Rouzier
R
, Mathieu
MC
, Uzan
S
, et al. Breast cancer stroma frequently recruits fetal derived cells during pregnancy
. Breast Cancer Res
. 2008
;10
(1
):R14
. 22.
Weiden
PL
, Flournoy
N
, Thomas
ED
, Prentice
R
, Fefer
A
, Buckner
CD
, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts
. N Engl J Med
. 1979
;300
(19
):1068
–73
. 23.
Holliday
DL
, Speirs
V
. Choosing the right cell line for breast cancer research
. Breast Cancer Res
. 2011
;13
(4
):215
. 24.
Bubba
F
, Pouchol
C
, Ferrand
N
, Vidal
G
, Almeida
L
, Perthame
B
, et al. A chemotaxis-based explanation of spheroid formation in 3D cultures of breast cancer cells
. J Theor Biol
. 2019
;479
:73
–80
. 25.
Comşa
Ş
, Cîmpean
AM
, Raica
M
. The story of MCF-7 breast cancer cell line: 40 years of experience in research
. Anticancer Res
. 2015
;35
(6
):3147
–54
.26.
Li
Z
, Liu
Y
, Tuve
S
, Xun
Y
, Fan
X
, Min
L
, et al. Toward a stem cell gene therapy for breast cancer
. Blood
. 2009
;113
(22
):5423
–33
. 27.
Zhao
X
, Li
J
. Research on the correlation between ultrasonographic features of breast cancer and expressions of ER, CD34 and p53
. J BUON
. 2018
;23
(2
):372
–7
.28.
Montemurro
F
, Ueno
NT
, Rondón
G
, Aglietta
M
, Champlin
RE
. High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends
. Clin Breast Cancer
. 2000
;1
(3
):197
–210
; discussion 210. 29.
Vredenburgh
JJ
, Madan
B
, Coniglio
D
, Ross
M
, Broadwater
G
, Niedzwiecki
D
, et al. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy
. Bone Marrow Transpl
. 2006
;37
(11
):1009
–15
. 30.
Cancelas
JA
, Querol
S
, Canals
C
, Picón
M
, Azqueta
C
, Solà
C
, et al. Peripheral blood CD34+ cell immunomagnetic selection in breast cancer patients: effect on hematopoietic progenitor content and hematologic recovery after high-dose chemotherapy and autotransplantation
. Transfusion
. 1998
;38
(11–12
):1063
–70
. 31.
Mohr
M
, Hilgenfeld
E
, Fietz
T
, Hoppe
B
, Koenigsmann
M
, Hoffmann
M
, et al. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy
. Clin Cancer Res
. 1999
;5
(5
):1035
–40
.32.
Nieto
Y
, Shpall
EJ
, McNiece
IK
, Nawaz
S
, Beaudet
J
, Rosinski
S
, et al. Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant
. Clin Cancer Res
. 2004
;10
(15
):5076
–86
. 33.
Li
T
, Zhang
C
, Ding
Y
, Zhai
W
, Liu
K
, Bu
F
, et al. Umbilical cord-derived mesenchymal stem cells promote proliferation and migration in MCF-7 and MDA-MB-231 breast cancer cells through activation of the ERK pathway
. Oncol Rep
. 2015
;34
(3
):1469
–77
. 34.
Mirabdollahi
M
, Haghjooyjavanmard
S
, Sadeghi-Aliabadi
H
. An anticancer effect of umbilical cord-derived mesenchymal stem cell secretome on the breast cancer cell line
. Cell Tissue Bank
. 2019
;20
(3
):423
–34
. 35.
Chao
KC
, Yang
HT
, Chen
MW
. Human umbilical cord mesenchymal stem cells suppress breast cancer tumourigenesis through direct cell–cell contact and internalization
. J Cell Mol Med
. 2012
;16
(8
):1803
–15
. 36.
Fu
X
, De Angelis
C
, Schiff
R
. Interferon signaling in estrogen receptor-positive breast cancer: a revitalized topic
. Endocrinology
. 2022
;163
(1
):bqab235
. 37.
Solary
E
, Prud’homme
JF
, Gauville
C
, Magdelenat
H
, Calvo
F
. Modulation of proliferation, estradiol receptors and estrogen regulated protein PS2/BCEI in human breast cancer cell lines by gamma interferon
. J Biol Regul Homeost Agents
. 1991
;5
(3
):98
–106
.38.
Heimes
AS
, Härtner
F
, Almstedt
K
, Krajnak
S
, Lebrecht
A
, Battista
MJ
, et al. Prognostic significance of interferon-γ and its signaling pathway in early breast cancer depends on the molecular subtypes
. Int J Mol Sci
. 2020
;21
(19
):E7178
. 39.
Welte
T
, Zhang
XHF
. Interleukin-17 could promote breast cancer progression at several stages of the disease
. Mediators Inflamm
. 2015
;2015
:804347
. 40.
Tsai
YF
, Huang
CC
, Lin
YS
, Hsu
CY
, Huang
CP
, Liu
CY
, et al. Interleukin 17A promotes cell migration, enhances anoikis resistance, and creates a microenvironment suitable for triple negative breast cancer tumor metastasis
. Cancer Immunol Immunother
. 2021
;70
(8
):2339
–51
. 41.
Chen
WC
, Lai
YH
, Chen
HY
, Guo
HR
, Su
IJ
, Chen
HHW
. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor
. Histopathology
. 2013
;63
(2
):225
–33
. 42.
Cochaud
S
, Giustiniani
J
, Thomas
C
, Laprevotte
E
, Garbar
C
, Savoye
AM
, et al. IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2
. Sci Rep
. 2013
;3
:3456
. 43.
Koslawsky
D
, Zaretsky
M
, Alcalay
R
, Mazor
O
, Aharoni
A
, Papo
N
. A bi-specific inhibitor targeting IL-17A and MMP-9 reduces invasion and motility in MDA-MB-231 cells
. Oncotarget
. 2018
;9
(47
):28500
–13
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
